When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

最后审阅: 17 Jan 2026
最后更新: 22 Jul 2022

小结

定义

病史和体格检查

关键诊断因素

  • presence of risk factors
  • amenorrhoea or oligomenorrhoea
  • infertility
  • galactorrhoea
  • loss of sexual desire (libido)
  • erectile dysfunction
  • visual deterioration (e.g., temporal hemianopia)
完整详情

其他诊断因素

  • osteoporosis
  • ophthalmoplegia
  • headaches
完整详情

危险因素

  • genetic predisposition (e.g., presence of mutation resulting in multiple endocrine neoplasia-1 [MEN-1], familial isolated pituitary adenoma [FIPA])
  • oestrogen therapy
  • male sex, 30 to 60 years of age
  • female sex, 20 to 50 years of age
完整详情

诊断性检查

首要检查

  • serum prolactin
  • pituitary MRI
  • computerised visual-field examination
完整详情

治疗流程

持续性治疗

pre-menopausal women

post-menopausal women

men

撰稿人

作者

Niamh Martin, MB ChB, PhD, FRCP

Reader in Endocrinology

Imperial Centre for Endocrinology

Department of Metabolism, Digestion and Reproduction

Imperial College London

London

UK

利益声明

NM declares that she has no competing interests.

鸣谢

Dr Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.

利益声明

IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.

同行评议者

Mark Molitch, MD

Professor

Division of Endocrinology

Northwestern University Feinberg School of Medicine

Chicago

IL

利益声明

MM is an author of a number of references cited in this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021 Dec;50(4):104080.全文  摘要

Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.全文  摘要

Xia MY, Lou XH, Lin SJ, et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018 Jan;59(1):50-61. 摘要

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას